The doctors removed the worm via a pars plana vitrectomy, a procedure in which the eye’s internal jelly-like vitreous humor ...

As my specialty practice has grown, I’ve developed an up-close understanding of both dry eye disease and the patients who ...

For two decades, I had to douse my eyes with artificial tears to get through the day. Then I decided to see if I could shop ...

Mission Vision, a public health initiative, has launched in India to combat the escalating crisis of vision loss due to ...

The American Society of Retina Specialists’ History of Retina is an initiative that highlights the milestones and the ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the ...

These promoters drive strong and specific gene expression in rod and cone photoreceptors even in mid-to-late stages of disease, outperforming most currently used promoters in retinal gene therapy.

Biotech Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2 By Darren Incorvaia May 19, 2025 12:59pm Atsena Therapeutics Cell & Gene Therapy eye disease retina ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management. Subscribe Now!

Opus Genetics announces upcoming presentations on gene therapy research for inherited retinal diseases at May 2025 conferences.